Health
Jaguar Health Provides Recap of November 8, 2025 Presentation on Groundbreaking Results of Proof-of-Concept Study of Crofelemer for Treatment of Pediatric Intestinal Failure at NASPGHAN Annual Meeting
Crofelemer can potentially extend and save lives of microvillus inclusion disease patients, reducing the volume of the total parenteral support (PS) necessary for them to survive Groundbreaking PS reduction of up to 37% is unprecedented; No approved ...
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Crofelemer can potentially extend and save lives of microvillus inclusion disease patients, reducing the volume of the total parenteral support (PS) necessary for them to survive","length":178,"tagName":"p"},{"type":"text","content":"Groundbreaking PS reduction of up to 37% is unprecedented; No approved treatments exist for MVID","length":96,"tagName":"p"},{"type":"text","content":"SAN FRANCISCO, CA / ACCESS Newswire / November 13, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today provided a recap of the November 8, 2025 presentation at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting describing the initial groundbreaking results of an independent investigator-initiated trial (IIT) of crofelemer in the UAE for treatment of pediatric intestinal failure, which includes patients with ‘intestinal failure' due to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF).","length":620,"tagName":"p"},{"type":"text","content":""The intestines of patients with the ultrarare genetic disorder MVID do not function properly, as is often the case with patients having intestinal failure due to short bowel syndrome. The intestines of these patients are unable to absorb the fluids, electrolytes and nutrients required to survive and thrive. Intestinal failure is a debilitating, lifelong condition that often requires patients to receive life-sustaining fluids, electrolytes and nutrients through intravenous administration, which consists of total parenteral nutrition (TPN) with supplemental intravenous fluids, which together constitute parenteral support (PS). Most intestinal failure patients require PS up to 7 days a week, and sometimes for 20 hours or more per day," said Lisa Conte, Jaguar's founder, president, and CEO.","length":812,"tagName":"p"},{"type":"text","content":"While crucial for these patients, total parenteral support is associated with significant toxicities to patients, similar to some toxicities associated with chemotherapy, often causing serious health problems including infections, metabolic complications, liver and kidney function problems - as well as a risk of neurodevelopmental delay. These symptoms may emerge at any time in intestinal failure patients, and often become life-threateni...